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Background: The need for low toxicity adjuncts to standard care chemotherapy in inoperable colorectal cancer,
with potential to improve outcomes and decrease the side-effect burden, is well recognised. Addition of the low
toxicity diet-derived agent, curcumin (the active ingredient of turmeric), to standard oxaliplatin-based therapy has
shown promise in numerous pre-clinical studies.
Methods/Design: This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil,
folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the
CUFOX trial. CUFOX comprises a Phase 1 dose-escalation study (3 + 3 + 3 design) to determine an acceptable
target dose of curcumin with which to safely proceed to a Phase IIa open-labelled randomised controlled trial.
Thirty three participants with histological or cytological confirmation of inoperable colorectal cancer will then be
randomised to oxaliplatin-based chemotherapy with the addition of daily oral curcumin at the target dose determined
in Phase I, or to standard care oxaliplatin-based chemotherapy alone (recruiting at a ratio of 2:1).
Discussion: Primary outcome measures will be the determination of a target dose which is both safe and tolerable
for long-term administration to individuals in receipt of first-line oxaliplatin-based chemotherapy for inoperable
colorectal cancer. Secondary outcome measures will include observation of any changes in neuropathic side-effects
of chemotherapy, improvement to progression-free or overall survival and identification of putative efficacy biomarkers
in plasma.
The results will be disseminated via presentation at national and international conferences, via publication in appropriate
peer-reviewed journals and via the Cancer Research UK/Department of Health Experimental Cancer Medicine Centre
Network. This trial has full ethical and institutional approval, and commenced recruitment in February 2012.
Trial registration: ClinicalTrials.gov (NCT01490996, registered 7th December 2011), European Drug Regulating
Authorities (EudraCT 2011-002289-19, registered 13th May 2011), UKCRN ID#10672.
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Background and rationale
Colorectal cancer (CRC) is the fourth most common
cancer worldwide. It carries the second highest cancer-
related mortality in Western countries with a lifetime in-
cidence of ~1 in 15 [1,2]. Up to a fifth of CRC patients
will present with metastatic disease, typically in the liver
[3], and half of those undergoing resection for primary
disease will develop metastases. The majority of these
patients are not amenable to curative surgery [4] and ex-
perience a 5-year survival rate of less than 10%. The me-
dian survival for patients with un-resectable colorectal
liver metastases in the absence of chemotherapy is
approximately 8 months [5], compared with up to
24 months with chemotherapy in patients with KRAS
(Kirsten rat sarcoma homologue) wild-type positive
cancers [6,7]. Unfortunately, approximately 40% of such
cancers display chemo-resistance from the outset and
eventually all will fail to respond.
The mainstay of chemotherapy for CRC in most
countries has been oxaliplatin-based, commonly with
5-fluorouracil (5-FU) and folinic acid, collectively known
as FOLFOX. In the UK in 2002, the National Institute of
Clinical Excellence first issued guidelines [8] for oxali-
platin to be combined with 5-FU/folinic acid and ad-
ministered as first-line therapy. Compared with many
cytotoxic regimens, FOLFOX is relatively well tolerated
but dose-limiting side-effects are common (reviewed in
National Institute of Clinical Excellence CG131 [8,9]).
Diarrhoea, due to mucositis, can occur in up to a third
of people receiving 5-FU [10], which can be life threat-
ening. Patients may develop neutropaenia, increasing
susceptibility to infection. The majority of patients (90%)
will develop oxaliplatin-induced peripheral sensory neu-
ropathy to some extent [11] and, after nine cycles, up to
a third of patients will require dose reduction or cessa-
tion [12].
Strategies for overcoming chemo-resistance and/or
augmenting the action of therapy are being investigated
with the aim of extending the time that chemotherapy
can be tolerated whilst maintaining efficacy and post-
poning resistance without increased drug toxicities.
Naturally occurring dietary agents are attractive in
this setting because they offer a potentially favourable
side-effect profile with good patient tolerability. Interest
in dietary agents has continued as evidence of anti-
carcinogenic activity increases (reviewed in [13]). Cur-
cumin is a derivative of the spice turmeric (Curcuma
longa), typical to Asian cuisine. The use of turmeric in
the field of medicine was described in Asia thousands of
years ago (reviewed in [14]). Of note, Asian populations
experience approximately an eighth of the incidence of
bowel cancer than that of Western populations (30.8
versus 3.9 cases per 100,000 in the UK and India,respectively) [2] and diet is likely to be an important
underlying factor.
Curcumin can interact beneficially with a wide variety
of pathophysiological processes including maintenance
of the cell cycle, carcinogenesis, wound healing and in-
flammation (reviewed in [15]). The effects of curcumin
in combination with chemotherapy have been explored
in a variety of cancer cell lines and in vivo models. There
is a growing body of pre-clinical evidence repeatedly
reporting reductions in tumour volume and metastatic
features when curcumin is combined with chemo-
therapy, as compared to either agent alone [16]. We
have previously reported that curcumin augments the
effect of oxaliplatin against CRC cell lines, and restores
efficacy in a cellular model of chemo-resistance [17].
Furthermore, these findings were reproduced using a
xenograft model, where a reduction in tumour size of
53% was observed following treatment with curcumin
and oxaliplatin compared to a 16% reduction following
treatment with oxaliplatin alone. These pre-clinical data
are compelling and have provided the rationale for clin-
ical investigation. Presently, two trials have provided
early evidence of efficacy for curcumin in patients with
inflammatory bowel disease. Efficacy of curcumin in the
cancer setting has not yet been effectively addressed.
Clinical reports of curcumin in combination with any
chemotherapy regimen are confined to three small trials
(two in pancreatic cancer [18,19] and one in metastatic
breast cancer patients [20]) plus a case report [21].
These were small studies, not powered for efficacy, and
lacked a control arm, but have provided evidence that
patients with advanced cancer receiving chemotherapy
can tolerate daily curcumin for several months alongside
their chemotherapy.
Objectives
The main aims of this study are to: establish a safe and
suitable dose of curcumin to administer to patients receiv-
ing up to 6 months of oxaliplatin-based chemotherapy;
collect patient samples for biomarker and pharma-
cokinetic analysis; record patient-reported outcomes, in-
cluding quality of life and peripheral neuropathy scores;
observe progression-free survival (PFS) and overall sur-
vival (OS).
Trial design
CUFOX (curcumin plus FOLFOX) is a Phase I dose-
escalation study rolling in to a Phase IIa randomised con-
trolled trial combining daily oral curcumin (C3-complex;
Sabinsa Corp., UT, USA) with standard care FOLFOX-
based chemotherapy in patients with histological diagnosis
of metastatic CRC and disease measurable by response
evaluation criteria for solid tumours (RECIST) 1.1, atten-
ding oncology clinics prior to chemotherapy. The study
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ditional expense of sourcing an appropriate placebo. Iden-
tification of a suitable placebo is also complicated by the
issue that curcumin (E100) is highly coloured and widely
used as a food colouring. For Phase IIa, participants
will therefore be randomised to FOLFOX+ curcumin or
FOLFOX only at a ratio of 2:1.
Methods/Design
Study setting
This study will recruit adults referred to the University
Hospitals of Leicester NHS Trust Oncology Department.
The study is sponsored by the University of Leicester
and will be undertaken at the University Hospitals of
Leicester NHS trust UK, as a single centre study.
Eligibility criteria
Inclusion criteria are: histological or cytological diag-
nosis of metastatic CRC; inoperable colorectal liver me-
tastases; disease measurable by RECIST 1.1; adequate
haematological, hepatic and renal function; age ≥18 years;
Eastern Cooperative Oncology Group performance sta-
tus 0 or 1; recovered from effects of any recent major
surgery; post-menopausal or willing to use contraception
if applicable; informed consent; life expectancy estimated
to be more than 12 weeks.
The exclusion criteria include: contraindications to
FOLFOX chemotherapy; peripheral neuropathy (National
Cancer Institute Common Terminology Criteria >1); liver
failure, uncontrolled coronary heart disease, myocardial
infarction within the previous 6 months; unwilling or
unable to comply with the study protocol; pregnant or lac-
tating or contemplating pregnancy; undergone chemo-
therapy (other than adjuvant for CRC) or participating in
another drug study; previous cancer <5 years (other than
colorectal, basal cell carcinoma, in-situ cervical cancer);
major surgery within 4 weeks of starting the study; poten-
tially operable liver disease without prior chemotherapy;
bone marrow depletion; co-existing active infection or ser-
ious concurrent medical condition; significant cardiovascu-
lar disease; severe valvular heart disease; congestive heart
failure requiring therapy (New York Heart Association
grade ≥2); bone metastases; brain or leptomeningeal me-
tastases; surgery or hospital admissions for symptomatic
intra-abdominal adhesions; colitis.
Intervention
The investigational medicinal product: curcumin
C3-complex curcumin is to be obtained in a single batch
with a shelf life of 3 years (Sabinsa Corp.). The raw pow-
der consists of 79.85% curcumin and 20.15% curcumi-
noids, and will be encapsulated in clear “00” capsules to
Good Manufacturing Practice standards by Novalabs
(Wigston, Leicester, UK). Approval for release will beprovided by a registered Qualified Person in accordance
with Medicines and Healthcare Product Regulatory
Authority standards. Each capsule will contain 500 mg
C3-complex with the addition of 5% (25 mg) magnesium
stearate lubricant to assist the semi-automated filling
process (capsule net weight 525 mg).
Curcumin will be given orally at 0.5, 1.0 or 2 g per
day. There will be a loading period of 1 week prior to
commencement of chemotherapy. Curcumin will be
taken daily at the specified dose throughout the course
of chemotherapy. Once chemotherapy ceases, partici-
pants will be deemed ‘off trial’ and curcumin interven-
tion will also cease.
Modifications and cessation for gastrointestinal
disturbances
Curcumin can produce diarrhoea in up to a third of pa-
tients. This is often mild and self-limiting. However, up to
a quarter of patients can develop grade 3/4 diarrhoea due
to 5-FU. Persisting grade 2 diarrhoea as a result of curcu-
min prior to receiving chemotherapy will require cessation
or reduction of curcumin. If diarrhoea occurs after chemo-
therapy commences, 5-FU modification will be in keeping
with local guidelines. Modification of curcumin dose will
be as per the guidance described in Table 1.
Adherence
Adherence will be monitored via means of a daily capsule
and symptom diary over the first 4 weeks, combined with
monitoring of capsule return over the study duration.
Concomitant chemotherapy (Phase I)/control group
(Phase II)
Participants in Phase I, or those randomised to the control
group, will receive standard care chemotherapeutic inter-
vention. Systemic FOLFOX-based chemotherapy will be
administered every 2 weeks for up to 12 cycles via central
venous catheter (body surface area capped at 2 m2). The
scheduling will be as follows: Hour 0: oxaliplatin 85 mg/m2
in 250 mL glucose 5%, 2-hour intravenous (IV) infusion;
folinic acid 350 mg in 250 mL glucose 5%, 2-hour IV
infusion. Hour +2: 5-FU bolus 400 mg/m2, IV bolus; 5-FU
continuous infusion 2,400 mg/m2, 46-hour continuous
IV infusion. Chemotherapy will be delayed (or reduced)
until all of the following conditions are met: neutro-
phils >1 × 109/L, platelets >75 × 109/L, full recovery from
stomatitis, National Cancer Institute Common Terminology
Criteria for Adverse Events grade ≤2 diarrhoea, skin or
other toxicity. Modifications to FOLFOX will be in line
with local procedures, and will be modified or discon-
tinued for one of the following reasons:
1. Objective evidence of tumour progression at any site
as determined by computed tomography/magnetic
Table 1 Definitions of diarrhoea and subsequent management according to the timing of symptoms in relation to
administration of study drugs
Diarrhoea grade
Definition/timing 1 2 3 4
Definition Increase <4 stools/day over
baseline; mild increase in
ostomy output











Pre-chemotherapy Observe but continue to
chemotherapy




Stop curcumin, continue with
chemotherapy when AE
grade <2
Stop curcumin, continue with
chemotherapy when AE
grade <2
During chemotherapy Observe but continue
chemotherapy
Reduce or stagger curcumin Stop curcumin, continue or










Stop curcumin, continue or
reduce chemotherapy as per
protocol
Stop curcumin, continue or
reduce chemotherapy as per
protocol
Stop curcumin, continue or
reduce chemotherapy as per
protocol
Symptoms were defined according to the Common Terminology Criteria for Adverse Events (Version 4). AE, adverse event.
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ultrasound and/or clinical examination.
2. Participant request.
3. Unacceptable toxicity as determined by objective
evidence, clinical judgment or patient request.
4. Alteration of national or local policy or the
availability of other potentially beneficial agents to
be used alongside FOLFOX (for example,
bevacizumab).
5. In the event of central line removal, infusional
therapy may be switched to capecitabine, and back
again if the line is re-inserted.
Any other treatment considered necessary for the
patients’ safety and well-being may be given at the dis-
cretion of the investigators, and will be carried out in
accordance with local practice.
Outcomes
Primary endpoints
Safety and tolerability of FOLFOX+ curcumin Phase I:
Completion of dose escalation in three consecutive par-
ticipants at four capsules (or two or one if de-escalation
occurs) of curcumin in combination with oxaliplatin
without adverse effects attributable to curcumin 1 week
after two cycles of chemotherapy.
Phase IIa: The completion of 12 cycles of chemo-
therapy (including dose reductions) or withdrawal from
therapy by the target population.
Secondary endpoints
Potential for improvement to PFS, OS and neuroto-
xicity scores in FOLFOX + curcumin versus FOLFOX
only group.Analysis of plasma for potential biomarkers of im-
proved efficacy and to assess levels of curcumin and its
metabolites.
Analysis of lymphocyte DNA to assess whether curcu-
min affects platinating abilities of oxaliplatin.
Participant timeline
The timeline of proposed interventions for this study
can be found in Table 2.
Sample size
This is the first study combining FOLFOX-based chemo-
therapy with curcumin, and so consequently there are
no published data on which to power this study. This
study will provide the first efficacy data for this regimen
that can be used in the powering of future studies. The
sample size for the Phase I dose escalation is pre-
determined by the 3 + 3 + 3 design. Phase IIa will provide
further information relating to long-term safety and
tolerability of this regimen, and efficacy is a secondary
outcome measure. Phase I will recruit between 9 and 18
participants, dependent on the observed rate of dose-
limiting toxicity. Phase II will recruit 33 participants, 22
of whom will receive FOLFOX-based chemotherapy in
combination with daily oral curcumin, and 11 of whom
will be randomised to the control arm receiving standard
care chemotherapy.
Recruitment
Potential participants will be identified via the weekly
cancer multidisciplinary team meetings and referrals to
oncology clinic. Participants who have been informed of
their diagnosis and are being offered chemotherapy will
be given or posted a patient information sheet (PIS).













EORTC QLQ-C30 X X
Curcumin questionnaire X X
Medical history X
Physical examination X
Weight, temperature, blood pressure, pulse X X X X
ECOG performance status (Appendix 2) X X
12-lead electrocardiogram X
Haematology, liver function, renal function2 X Performed as routine prior to each cycle of FOLFOX
Urine sample (pregnancy test for female patients) X
Tumour assessment3 X 3-monthly CT scan to 24 months.
6-monthly CT 24 to 48 months when appropriate
Serum CEA2 X 3-monthly CEA until CT scans end
Symptom diary X Daily for first 4 weeks
Neurotoxicity questionnaire X Questionnaire every 2 cycles, after cycle 12 or withdrawal
Blood samples for curcumin, platinum and
biomarker analysis
X X X X X4
FOLFOX treatment5 Up to 12 cycles, at 2 week intervals
Survival Continuously monitored once protocol therapy has ended6
1Can be obtained at any point prior to start of trial. 2Patients on folinic acid/5-fluorouracil/oxaliplatin (FOLFOX) chemotherapy will routinely have these blood tests
done prior to each cycle. 3If no radiological assessment of disease (computed tomography (CT)/magnetic resonance imaging (MRI) of chest, abdomen and pelvis)
has been done within 28 days of screening, a trial baseline scan (CT/MRI of chest, abdomen and pelvis) must be completed within 28 days of the patient’s first
cycle of chemotherapy. CT scans should be repeated every six cycles (12 weeks) during FOLFOX and then 3-monthly to 24 months and 6-monthly to 48 months.
4Research samples after final cycle should be as close to 14 days as possible, but more than 7 and can be arranged to coincide with the next clinic appointment.
5FOLFOX will be up to 12 cycles (approximately 24 weeks). Central line is placed prior to chemotherapy by trained staff. 6Direct patient involvement in the trial
will cease after curcumin has been completed. Patient episodes following this will be confined to follow-up CT scans. Patients will remain in the standard care
pathway. CEA, chorioembryonic antigen; ECOG, Eastern Cooperative Oncology Group; EORTC-QLQ30: European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire form 30.
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they will be introduced to a trial investigator usually by
the oncologist arranging the chemotherapy. The investi-
gator will discuss the trial and PIS and answer any ques-
tions that potential participants may have. They will be
given a minimum of 24 hours to consider the PIS before
being invited to participate in the study. Patients can be
seen at their second pre-chemotherapy clinic appointment
to obtain written informed consent. Upon obtaining
written informed consent from each participant, baseline
evaluations can be undertaken. Baseline evaluations will
include a complete physical examination (body weight,
height; pulse, and assessment of Eastern Cooperative
Oncology Group performance status). Body surface area
must also be determined for FOLFOX dosing. Required
haematological and clinical chemistry measurements
will include haemoglobin, white blood cell count with
differential if abnormal, platelet count, urea, creatinine,
sodium, potassium, alkaline phosphatase, alanine ami-
notransferase, albumin, and bilirubin. Chorioembryonicantigen will be measured in all patients at baseline and,
if elevated, every 12 weeks thereafter.
Phase I traditional escalation response model (3 + 3 + 3)
study
The sample size for Phase 1 is determined by the maxi-
mum dose desired (2 g/day based on previous trials
within the local populace) and the number of tiers se-
lected to step up to this dose (three tiers; 500 mg/day,
1 g/day and 2 g/day). In the absence of dose-limiting
toxicity (DLT), only three patients per tier will be
required (n = 9); however, the “worse-case” scenario is
taken into consideration, allowing resources to repeat
each tier once if necessary (n = 18).
Three patients meeting the inclusion criteria will receive
one oral capsule (500 mg) per day of curcumin (Figure 1),
commencing 7 days prior to chemotherapy to allow accli-
matisation and any curcumin-induced adverse events
(AEs) to manifest prior to chemotherapy. In the absence
of curcumin-related toxicity after 1 week, patients will
Figure 1 Trial schema for Phase 1 traditional escalation response. CT, computed tomography; DLT, dose-limiting toxicity; FOLFOX, folinic
acid/5-fluorouracil/oxaliplatin; QLQ-C30, Quality of Life Questionnaire C-30; RECIST, response evaluation criteria for solid tumours.
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(modified to capecitabine + oxaliplatin, or FOLFOX + bev-
acizumab where appropriate). After a 4-week enhanced
early monitoring phase, and in the absence of curcumin-
associated dose-limiting toxicity (DLT) in three consecu-
tive patients, a further three participants will be recruited
at 1 g/day oral curcumin (two capsules), and then to the
maximum target dose of 2 g/day (four capsules). In the
event of a DLT attributable to curcumin, the participantwill cease involvement in the trial and a further three par-
ticipants will be recruited at that dose level. If a participant
withdraws for a reason unrelated to curcumin, only that
participant will be replaced. Independent data monitoring
will be convened prior to each dose escalation and prior
to commencement of Phase II to ensure patient safety.
De-escalation will be mandatory if more than two DLTs
due to curcumin among six participants are observed
within 4 weeks of commencing curcumin.
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Phase II will be an open-labelled, two-armed, rando-
mised controlled trial/feasibility study, consisting of a
FOLFOX only (control) group (11 participants) and a
FOLFOX + curcumin group (22 participants). Patients
will be managed identically to those recruited to the
traditional escalation response model. Primary endpoints
will remain focussed on drug safety, tolerance and the
feasibility of undertaking a larger scale study. A group
receiving chemotherapy alone is to be included prin-
cipally to provide control samples for the proposed bio-
marker studies, but also to generate data informing on
quality of life, disease response, PFS, OS and neuro-
pathic side-effects.
Randomisation for Phase II
Consecutive unique identifying numbers (1 to 33) will be
assigned a group via an electronic random number gene-
rator at a ratio of 2:1 (number 1 = combination therapy;
number 2 = control group receiving FOLFOX-based the-
rapy only). Groupings will be placed in a sealed envelope
bearing the unique identifying number. These will be
blinded to the recruiting researchers and patients until in-
formed consent is obtained, whereupon grouping can be
revealed. The randomisation list is to be kept separate to
the site file and a copy held by the trial pharmacist.
Data collection
Quantitative data
Clinical response and survival will be monitored as per
standard care protocols. Computed tomography scans will
measure disease response using RECIST 1.1 [22] until
progression is observed. OS data will be obtained at the
end of the trial, defined by death of the last patient
recruited, from the regional cancer network database.
AE and serious adverse event (SAE) reporting will be
conducted using National Cancer Institute Common
Terminology Criteria AE version 4 (US Department of
Health and Human Services, 2010), in accordance with
both the Medicines for Human Use (Clinical Trials)
regulations 2004 (SI2004/1031; SI2006/1938) and Inter-
national Conference on Harmonisation Good Clinical
Practice. Routine haematological and biochemical ana-
lyses will be performed as per standard care prior to
each chemotherapy cycle. Expected AEs associated with
curcumin are likely to be gastrointestinal in nature, con-
sisting primarily of diarrhoea, nausea and bloating. It is
currently unknown as to whether addition of curcumin
to FOLFOX-based chemotherapy may increase known
gastrointestinal side effects of 5-FU.
Further to collection of quantitative safety data, a
variety of laboratory research measures will be assessed.
Research bloods will be taken at baseline, end of week 1,
prior to the 2nd and 3rd cycles of chemotherapy, andupon completion or withdrawal from the study. Briefly,
curcumin and metabolites will be extracted from plasma
and undergo chromatographic analysis using a high
performance liquid chromatography-ultraviolet assay de-
veloped and validated in-house. Proposed biomarker
studies include in-house high-definition mass spectro-
metry, proteomic analysis of plasma for prospective iden-
tification of markers of curcumin efficacy, and analysis of
circulating tumour microRNA. In addition, quantification
of platinated lymphocyte DNA will be undertaken using
inductively-coupled plasma mass spectrometry to assess
whether curcumin may interfere with DNA adduct forma-
tion by oxaliplatin [17,23].
Qualitative data
A neuropathic scoring questionnaire [24] will be com-
pleted by patients every two cycles throughout protocol
chemotherapy, and subjects will also record the amount
and timing of curcumin doses alongside any side-effects
experienced as part of the early monitoring period. A
28-day diary has been designed to support monitoring
during the early monitoring period. The European
Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire form C30 will be com-
pleted at the beginning of the trial and when participants
cease protocol chemotherapy. Non-validated pre- and
post-trial questionnaires relating to participant’s views
on curcumin, its consumption, side-effects and the trial
experience will be completed at the start and end of the
curcumin course.
Data management
Data will be abstracted from the participant’s records
onto paper case report forms. Data collection and ar-
chiving will be done in accordance with appropriate
standard operating procedures. Case report forms are
kept in secure storage within a locked room/building
and personal data is kept to a minimum. Complete
patient identifiable details will be stored on a separate
paper recruitment log. Transcription accuracy will be
cross-checked on a quarterly basis, with audit trail and
responses filed in the Trial Master Site File.
Data analysis and statistical methods
Data will be presented in summary format. This will pre-
dominantly take the form of counts or percentages for
categorical outcome data with mean/median, range and
standard deviations for continuous outcome data and with
95% confidence intervals where appropriate. Additional in-
dependent samples t-test or unpaired non-parametric tests
will be performed with P < 0.05 taken as significant. Esti-
mated survival times will be calculated from clinical out-
come data. Statistical comparison can be made between
groups; however, this study is not primarily powered to be
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rated herein is intended for the design of future clinical
trials. The statistical software at the University of
Leicester is SPSS/PASW (Chicago, IL, USA). Statistical
analyses will be supported by the University of Leicester’s
Bioinformatics and Biostatistics Hub.
Data monitoring and auditing
An independent data monitoring committee will be con-
vened to provide safety monitoring prior to dose escal-
ation in Phase I. The committee will subsequently meet
on a quarterly basis to review any AEs, SAEs, SUSARs
(Suspected Unexpected Serious Adverse Reaction) and
other safety issues arising in Phase IIa. This committee
may be convened at an earlier date in the event of sig-
nificant safety concerns relating to the study drug. The
study will audited by an external auditor every 6 months,
in keeping with Sponsor and Institutional policies.
Ethics and dissemination
Ethical approval for this study was granted by the East
Midlands (Derby 1) regional ethics committee (11/EM/
0263). Clinical trials approval was obtained from the
Medicines and Healthcare Products Regulatory Agency.
The trial is registered at ClinicalTrials.gov (NCT01490996)
and with the European Drug Regulating Authorities
(EudraCT 2011-002289-19), and will be conducted in ac-
cordance with good clinical practice and the principles of
the Declaration of Helsinki.
Written informed consent will be obtained by dele-
gated members of the participant’s healthcare team.
Consent will be sought from participants to allow sec-
tions of their medical records to be looked at in strict
confidence by responsible individuals from the study
team, the Sponsor, Research Ethics Committee, NHS
Trust or from regulatory authorities where relevant.
Research findings will be reported at local levels on
University Hospitals of Leicester NHS Trust and University
of Leicester websites. National and international disse-
mination of results will take place at oncology-based
conferences such as those hosted by the National Cancer
Research Institute, British Association for Cancer Research,
and American Society of Clinical Oncology. Furthermore,
results will be disseminated in both lay and scientific sum-
mary format via the websites of major funders for this study
including Hope against Cancer, The Royal College of
Surgeons, the Bowel Disease Research Foundation, the
Cancer Research UK Experimental Cancer Medicine Centre
Network and the Cancer Research UK Leicester Centre.
Discussion
This will be the first clinical trial to investigate outcomes
from the combination of oral curcumin with standard
care oxaliplatin-based chemotherapy.The target dose of 2 g/day oral curcumin has been
chosen for three reasons. Firstly, our pilot study [25]
showed that whilst compliance was excellent (92%)
amongst patients receiving 2.35 g taken in five daily cap-
sules, participant questionnaires revealed a potential re-
luctance to take larger doses which would necessitate
either a greater number or size of capsule; secondly, AEs
may increase at doses in excess of 4 g, and greater cau-
tion must be observed in the presence of chemotherapy;
thirdly, the dose required to exert pharmacological effect
remains unknown.
A mouse model of polyp prevention demonstrating ef-
ficacy of curcumin proposes that 1.6 g per day delivered
in a single dose to humans is likely to be sufficient [26].
Curcumin has been detected in plasma of patients re-
ceiving 2 g daily oral curcumin, and high-performance
liquid chromatography analysis of portal blood and
hepatic tissue suggests that 3 to 4 g may be sufficient for
activity in organs distal to the gut. Two grammes once a
day is expected to be both a well-tolerated amount of
curcumin yet also possess the potential to invoke a
clinical response. At higher doses, participant com-
pliance is likely to decrease and AEs increase [27,28].
As the side-effect profile of curcumin in combination
with FOLFOX-based therapy is unknown, a dose escala-
tion arm is mandated. In controlled trials researching
curcumin as a single agent, the AE incidence has been
similar for both control and treatment arms [29-32]. In
the study by He and colleagues, which recruited patients
with CRC in to a treatment and control group, 10/37
(27%) patients taking curcumin experienced diarrhoea
compared with 8/32 (25%) in the placebo group [31].
Despite this, diarrhoea does appear to be a frequent side
effect of curcumin [33-35], although AE symptoms are
usually brief and mild.
The second phase of this trial will look more closely for
potential differences to the side-effect profile of FOLFOX
brought about by the addition of curcumin, via the in-
clusion of a control (FOLFOX only) arm. A further novel
aspect of this study is to explore the putative anti-
neuropathic properties of curcumin (extensively reported
in pre-clinical models [36-38]) by use of a peripheral neu-
ropathy scoring system.
To date, there are no studies providing evidence for
clinical efficacy of the low-cost, low-toxicity diet-derived
agent curcumin in the treatment of cancer. Relative risk
or OS have been reported by studies involving small and
heterogenous patient groups taking curcumin alone [18]
or combined with chemotherapy [19,20,28], and curcu-
min does not appear to impact negatively on survival.
These studies have reported that it is both safe and fea-
sible to combine curcumin with chemotherapy for several
months in cancer patients, but that larger randomised
control trials are required to investigate the efficacy of
Irving et al. Trials  (2015) 16:110 Page 9 of 10curcumin-chemotherapy regimens. CUFOX is the first
randomised controlled trial of its kind and has the poten-
tial to provide early evidence of clinical efficacy of curcu-
min within the chemotherapeutic setting.
Trial status
At the time of article submission, the CUFOX trial has re-
cruited 18 of 33 participants to the Phase 2 randomised
controlled trial component of the study.
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